Goldman Sachs analyst Sumeet Jain downgrades Infosys (NYSE:INFY) from Buy to Sell.
Another Competitor For Amgen As FDA Approves Mirati Therapeutics’ KRAS Inhibitor For Lung Cancer Setting
The FDA granted accelerated approval to Mirati Therapeutics Inc (NASDAQ:MRTX) Krazati (adagrasib), a targeted treatment option for adult patients with KRASG12C-mutated locally…